No Data
No Data
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
Express News | Daiichi Sankyo And AstraZeneca's ENHERTU Receives Breakthrough Therapy Designation In The U.S. For Specific Patients With HER2 Low Or Ultralow Metastatic Breast Cancer
J&J, Roche Come Out on Top in S&P Ratings of Strongest Pharma Companies
Trending Stocks This Week as U.S. Equities Notch Their Best Week of 2024
How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?
Astrazeneca's (AZN.US) blockbuster drug Imfinzi's lung cancer label expands in the US market.
AstraZeneca announced on Friday that the Food and Drug Administration (FDA) in the USA has approved its heavyweight anti-PD-L1 immunotherapy drug Imfinzi (durvalumab) for another indication of lung cancer.
Ryand83 OP : $ROCHE HOLDING AG (RHHBY.US)$ $AstraZeneca (AZN.US)$
Ryand83 OP : meant to say 40B
not 50B. Point is that Roche would be dummies to screw us over